XFXiaoxuan Fan

Xiaoxuan Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoxuan Fan has a total of 206 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron P. Rapoport

    Department of Medicine and Transplant/Cell Therapy Program, University of Maryland School of Medicine and Marlene and Stewart Greenebaum, Baltimore, USA

    4 shared publications
  • Djordje Atanackovic

    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA

    4 shared publications
  • Daniel Yamoah

    Department of Medicine and Transplant/Cell Therapy Program, University of Maryland School of Medicine and Marlene and Stewart Greenebaum, Baltimore, USA

    3 shared publications
  • Destiny Omili

    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, USA

    3 shared publications
  • Hancai Dan

    Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.

    3 shared publications
  • Kenneth A. Dietze

    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA

    3 shared publications

Latest Publications

  • Endoplasmic Reticulum Membrane Insertion of APOL1 Risk Alleles Disrupts Calcium Homeostasis and Is Mitigated by Autophagic Clearance

    by Jin-Gu Lee, Jun-Yi Zhu, Xiaoxuan Fan, Patricio E. Ray, Zhe Han

    Background: Apolipoprotein 1 ( APOL1 ) risk alleles (G1 and G2) are major genetic drivers of APOL1 -associated kidney disease in populations of African ancestry. Prior studies implicated membrane-associated channel activity and ion dysregulation in APOL1 cytotoxicity, but how APOL1 risk alleles engage intracellular membranes, disrupt endoplasmic reticulum calcium, and are handled by quality-control pathways remains incompletely defined. Methods: We used a split-green fluorescent protein topology system to visualize and quantify APOL1 membrane insertion and domain-deletion mutants to define structural requirements for insertion and toxicity. Endoplasmic reticulum calcium was monitored using a genetically encoded fluorescent, endoplasmic reticulum-specific calcium indicator. APOL1 degradation was assessed using autophagy and proteasome modulators, immunoblotting, and LC3 colocalization. In vivo relevance was tested in transgenic Drosophila nephrocytes expressing human APOL1 alleles with or without dietary rapamycin. Results: APOL1 inserted robustly into the endoplasmic reticulum membrane under basal cellular conditions, and its pore-forming and membrane-addressing domains contributed strongly to insertion and cytotoxicity. APOL1-G1 and APOL1-G2 showed greater endoplasmic reticulum membrane insertion than APOL1-G0, accompanied by greater endoplasmic reticulum calcium depletion. These findings support a model in which risk allele-associated misfolding exposes hydrophobic regions that promote aberrant endoplasmic reticulum membrane engagement. APOL1 accumulated after autophagy inhibition, decreased after rapamycin treatment, and localized to LC3-positive autophagosomal structures, whereas proteasomal inhibition did not accumulate APOL1 nor induce its toxicity. Rapamycin reduced APOL1 protein levels, improved cell viability, and mitigated risk allele-induced nephrocyte hypertrophy and filtration dysfunction in vivo . Conclusions: These findings identified enhanced endoplasmic reticulum membrane insertion, endoplasmic reticulum calcium depletion, and autophagy-lysosomal clearance as linked features of APOL1 risk allele toxicity.

  • Longitudinal Surgical Modeling of Early Glioblastoma Recurrence Reveals Emergence of Margin-Associated Neural Programs

    by Adarsha P. Malla, Matthew Flick, Jennifer R. Fang, Xiaoxuan Fan, Chixiang Chen, Angad Beniwal, Chris Sereduk, Richard Drexler, Alexandros Poulopoulos, Michelle Monje, et al.

    Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron–glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurologic function and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) platform. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multiregional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of postsurgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary versus postsurgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron–glioma signaling. Overall, the MSIS approach offers opportunities to model the standard of care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology. Significance: A clinically derived stereotactic resection platform models surgical resection in glioblastoma, enabling longitudinal tissue sampling and revealing conserved early-recurrence neuron-glioma programs in patient-derived models.

  • Beta-2 Adrenergic Receptor in CD8+ T Cells Inhibits Graft-versus-Host Disease through Transcriptional Modulation of Differentiation and Exhaustion

    by Sayon Basu, Rachel Massalee, Habeebat Aderonke Mustapha, Mohammad A. Alzubi, Chang-Yong Choi, Xiaoxuan Fan, Xuefang Cao

  • Open Access

    Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function

    by Kenneth A. Dietze, Kiet Nguyen, Aashli Pathni, Frank Fazekas, Wenxiang Sun, Ethan Rosati, Jillian M. Baker, Maday Galeana Figueroa, Etse Gebru, Daniel Yamoah, et al.

    Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in cancer treatment. Nevertheless, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells. CMT results in the emergence of antigen-negative tumor cells, which can evade future CAR detection, and antigen-positive CAR T cells, which have been suggested to cause CAR T-cell fratricide and exhaustion. Whether CMT indeed causes CAR T-cell dysfunction and the molecular mechanisms conferring CMT remain unknown. Using a selective degrader of trogocytosed antigen in CAR T cells, we show that the presence of trogocytosed antigen on the CAR T-cell surface directly causes CAR T-cell fratricide and exhaustion. By performing small molecule screening using a custom high-throughput CMT screening assay, we found that the cysteine protease cathepsin B is essential for CMT and that inhibition of cathepsin B is sufficient to prevent CAR T-cell fratricide and exhaustion, leading to improved long-term in vitro and in vivo CAR T-cell persistence and in vitro antitumor activity. Our data demonstrate that it is feasible to separate CMT from cytotoxic activity, that CAR T-cell persistence, a key factor associated with clinical CAR T-cell efficacy, is directly linked to cathepsin B activity in CAR T cells, and that it is possible to improve CAR T-cell function through selective inhibition of CMT.


  • Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8 + T cells during chronic HIV-1 infection

    by Guangming Li, Yaoxian Lou, Jianping Ma, Liang Cheng, Haisheng Yu, Ourania Tsahouridis, Xiuting He, Masaya Funaki, James Ahodantin, Wenwen Bi, et al.

    Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.


  • Open Access

    Inhibition of autophagy-lysosomal function exacerbates microglial and monocyte lipid metabolism reprograming and dysfunction after brain injury

    by Marta Lipinski, Amir Mehrabani-Tabari, Nivedita Hegdekar, Brian R. Herb, Sazia Arefin Kachi, Chinmoy Sarkar, Sagarina Thapa, Dexter Nguyen, Yulemni Morel, Mehari Weldemariam, et al.

    CNS has an overall higher level of lipids than all tissues except adipose and contains up to 25% of total body cholesterol. Recent data demonstrate a complex crosstalk between lipid metabolism and inflammation, suggesting potential contribution of the lipid-rich brain environment to neuroinflammation. While recent data support the importance of brain lipid environment to inflammatory changes observed in age related chronic neurodegenerative diseases, in vivo interactions between lipid environment, lipid metabolism and neuroinflammation in acute brain disease and injury remain poorly understood. Here we utilize a mouse model of traumatic brain injury (TBI) to demonstrate that acute neurotrauma leads to widespread lipid metabolism reprograming in all microglial and brain associated and infiltrating monocyte populations. Additionally, we identify unique microglial and monocyte populations with higher degree of lipid metabolism reprograming and pronounced accumulation of neutral storage lipids, including cholesteryl esters and triglycerides. These lipids accumulate not only in lipid droplets but also in the microglial and monocyte lysosomes and are associated with lysosomal dysfunction and inhibition of autophagy after TBI. Our data indicate that lipid accumulation in these cells is the result of altered lipid handling rather than lipid synthesis and is triggered by phagocytosis of lipid-rich myelin debris generated after TBI. Finally, we use mice with autophagy defects in microglia and monocytes to demonstrate that further inhibition of autophagy leads to more pronounced lipid metabolism reprograming and exacerbated cellular lipid accumulation. Our data suggest a pathological feedback loop, where lipid phagocytosis causes inhibition of autophagy-lysosomal function, which in turn exacerbates cellular lipid retention, reprograming and inflammation.


  • Top Cited Papers
    Open Access

    Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

    by Djordje Atanackovic, Tim Luetkens, Dina Schneider, Peirong Hu, Xu Wang, Amol C. Shetty, Luke Tallon, Imari Patel, Rohan Singh, Etse Gebru, et al.

    We performed the first in-depth, comparative and prospective biomonitoring of Multiple Myeloma (MM) patients (N = 39) receiving ciltacabtagene autoleucel (cilta-cel) or idecabtagene vicleucel (ide-cel) chimeric antigen receptor T cells (CAR T) in the real-world setting. In cilta-cel patients response rates were higher and atypical neurotoxicities/infections more frequent. Peak CAR T counts were significantly higher in cilta-cel patients, driven by CD4+ CAR expansion, correlating with clinical responses. Expansion of cilta-cel cells was associated with higher CAR and CD27 expression while, in contrast to ide-cel, there was no correlation between TIM3 expression and CAR T proliferation. Cilta-cel CAR T expansion was followed by a CAR-specific switch from proliferation-associated genes to genes/surface markers indicating effector/memory function. The longer persistence of cilta-cel CAR T was associated with increased IL-7R expression; in vitro data showed persistent antigen-independent activation and higher metabolic activity of cilta-cel vs. ide-cel CAR T. Among cilta-cel-treated patients experiencing atypical neurotoxicities, central nervous system (CNS)-infiltrating, effector-type CAR T presented a distinct inflammatory phenotypic/cytokine-expression profile. This in-depth biomonitoring report following real-world cilta-cel or ide-cel highlights intrinsic biological differences between BCMA-targeting CAR T products, potentially explaining differences in clinical activity and toxicity. Our findings may guide optimization of cellular immunotherapy strategies in MM.


  • Open Access

    Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells

    by Mehmet H. Kocoglu, Tim Luetkens, Jacqueline T. Bork, John Baddley, Destiny Omili, Etse Gebru, Rediet Mulatu, Daniel Yamoah, Thierry Iraguha, Xiaoxuan Fan, et al.


  • Open Access

    Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia

    by Tejashree Joglekar, Alexander Chin, Alin Voskanian-Kordi, Seungchul Baek, Azim Raja, Apurv Rege, Weiliang Huang, Maureen Kane, Marikki Laiho, Thomas R. Webb, et al.

    Provirus integration site for Moloney murine leukemia virus (PIM) family serine/threonine kinases perform protumorigenic functions in hematologic malignancies and solid tumors by phosphorylating substrates involved in tumor metabolism, cell survival, metastasis, inflammation, and immune cell invasion. However, a comprehensive understanding of PIM kinase functions is currently lacking. Multiple small-molecule PIM kinase inhibitors are currently being evaluated as cotherapeutics in patients with cancer. To further illuminate PIM kinase functions in cancer, we deeply profiled PIM1 substrates using the reverse in-gel kinase assay to identify downstream cellular processes targetable with small molecules. Pathway analyses of putative PIM substrates nominated RNA splicing and ribosomal RNA (rRNA) processing as PIM-regulated cellular processes. PIM inhibition elicited reproducible splicing changes in PIM-inhibitor–responsive acute myeloid leukemia (AML) cell lines. PIM inhibitors synergized with splicing modulators targeting splicing factor 3b subunit 1 (SF3B1) and serine-arginine protein kinase 1 (SRPK1) to kill AML cells. PIM inhibition also altered rRNA processing, and PIM inhibitors synergized with an RNA polymerase I inhibitor to kill AML cells and block AML tumor growth. These data demonstrate that deep kinase substrate knowledge can illuminate unappreciated kinase functions, nominating synergistic cotherapeutic strategies. This approach may expand the cotherapeutic armamentarium to overcome kinase inhibitor–resistant disease that limits durable responses in malignant disease.


  • Open Access

    Aberrant GPA expression and regulatory function of red blood cells in sickle cell disease

    by Juliana N. Marshall, Matthew N. Klein, Pratap Karki, Kamoltip Promnares, Saini Setua, Xiaoxuan Fan, Paul W. Buehler, Konstantin G. Birukov, Gerardo R. Vasta, Magali J. Fontaine

    Glycophorin A (GPA), a red blood cell (RBC) surface glycoprotein, can maintain peripheral blood leukocyte quiescence through interaction with a sialic acid–binding Ig-like lectin (Siglec-9). Under inflammatory conditions such as sickle cell disease (SCD), the GPA of RBCs undergo structural changes that affect this interaction. Peripheral blood samples from patients with SCD before and after RBC transfusions were probed for neutrophil and monocyte activation markers and analyzed by fluorescence-activated cell sorting (FACS). RBCs were purified and tested by FACS for Siglec-9 binding and GPA expression, and incubated with cultured endothelial cells to evaluate their effect on barrier function. Activated leukocytes from healthy subjects (HS) were coincubated with healthy RBCs (RBCH), GPA-altered RBCs, or GPA-overexpressing (OE) cells and analyzed using FACS. Monocyte CD63 and neutrophil CD66b from patients with SCD at baseline were increased 47% and 27%, respectively, as compared with HS (P = .0017, P = .0162). After transfusion, these markers were suppressed by 22% and 17% (P = .0084, P = .0633). GPA expression in RBCSCD was 38% higher (P = .0291) with decreased Siglec-9 binding compared with RBCH (0.0266). Monocyte CD63 and neutrophil CD66b were suppressed after incubation with RBCH and GPA-OE cells, but not with GPA-altered RBCs. Endothelial barrier dysfunction after lipopolysaccharide challenge was restored fully with exposure to RBCH, but not with RBCSCD, from patients in pain crisis, or with RBCH with altered GPA. Pretransfusion RBCSCD do not effectively maintain the quiescence of leukocytes and endothelium, but quiescence is restored through RBC transfusion, likely by reestablished GPA-Siglec-9 interactions.